SpyGlass Pharma, Inc. SGP
34.97 USD +0.79 (+2.31%)
At closeNov 11, 2026, 4:00 PM EST
34.97 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
33.25 Day range 35.53
17.06 52-week range 39.92
- YTD
- +32.46%
- 1 year
- +32.46%
News
benzinga.com SpyGlass Pharma Q3 EPS $(0.73) Misses $(0.63) Estimate SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.63) by 15.87 percent. This is a 83.89 percent increase over losses of…
globenewswire.com SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates IRVINE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today reported recent business…
globenewswire.com SpyGlass Pharma to Participate in Upcoming Investor Conferences IRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”), a late-stage biopharmaceutical company, today announced that members of the…
benzinga.com HC Wainwright & Co. Reiterates Buy on SpyGlass Pharma, Maintains $37 Price Target HC Wainwright & Co. analyst Yi Chen reiterates SpyGlass Pharma (NASDAQ:SGP) with a Buy and maintains $37 price target.
benzinga.com SpyGlass Pharma Announces Trial Results From Bimatoprost Drug Pad-IOL System In Participants With Mild-To-Moderate Open Angle Glaucoma Reduces Mean IOP By 37% Across All Three Dose Cohorts; 86% Participants Remained Off All Topical IOP-Lowering Drops SpyGlass Pharma, Inc. (Nasdaq: SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye